PetVivo receives $200K from partial exercise of Series B Convertible Preferred purchase option

PetVivo Holdings, Inc.

Received $200,000 on June 16, 2025; total $1,000,000 received under $5M Series B Preferred offering.
Remaining $4,000,000 purchase option exercisable by investor; anticipated receipt by June 26, 2025.
Series B Preferred shares priced at $1.00 each, convertible 1:1 into common stock.
Securities sold to accredited investor under Section 4(a)(2) exemption; shares are restricted.
Proceeds to fund commercialization of Spryng™ with OsteoCushion™ Technology and PrecisePRP, clinical trials, and working capital.

item 1.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.